Treasury's new China rule puts biotech in the crosshairs for the first time

The US Treasury's proposed rule, published October 22, extends outbound-investment restrictions beyond chips and AI into biotechnology for the first time, covering bio-derived compounds, biomanufacturing equipment, gene-sequencing tools and brain-computer interfaces, according to Politico's reporting. A reported $50,000 threshold would catch private deals and venture rounds while leaving most ordinary stock purchases untouched. That distinction matters because American pharma companies have leaned heavily on Chinese biotech for drug discovery partnerships, and those arrangements now sit inside a 46-day comment window that closes December 7. Treasury isn't banning China exposure outright. It's forcing every US venture fund and pharma dealmaker to run a new compliance check before the next term sheet.